Abstract
The pharmacokinetics of recombinant murine interferon-gamma (rMuIFN-gamma) administered alone and in combination with recombinant hybrid human interferon-alpha (rHuIFN-alpha A/D-[Bgl]) were studied following intravenous (i.v.) and intramuscular (i.m.) injections into mice. The concomitant influence of these IFNs on splenic natural killer (NK) cell function was also examined. The coinjection of both IFNs did not affect the pharmacokinetics of either after i.v. administration. However, simultaneous injection of both IFNs i.m. does result in statistically significant changes in the serum concentrations of rHuIFN-alpha A/D(Bgl). The clinical benefits of the increased bioavailability of rHuIFN-alpha A/D(Bgl) are not apparent since NK cell enhancement after both IFNs were injected together was the same as that obtained after injection of rHuIFN-alpha A/D(Bgl) alone. NK cell enhancement after both IFNs were injected together was the same as that obtained after injection of rHuIFN-alpha A/D(Bgl) alone. Correspondingly, the coinjection of both IFNs did not affect the pharmacokinetics of either.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
